Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02624375
Other study ID # STUDY00001399
Secondary ID 53354
Status Completed
Phase Phase 4
First received
Last updated
Start date February 2016
Est. completion date November 2019

Study information

Verified date December 2019
Source University of Washington
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to learn more about the immune response to varicella zoster virus (VZV).


Description:

Participants 70 years of age or older will receive the FDA-approved shingles vaccine (Zostavax). Blood samples and optional skin biopsies will be obtained before and after vaccination to study the immune responses to shingles vaccination.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date November 2019
Est. primary completion date November 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 70 Years and older
Eligibility Inclusion Criteria:

- 70 years of age or older.

- History of chickenpox.

Exclusion Criteria

- Previous vaccination with Zostavax or with the chickenpox vaccine.

- History of ever having had shingles.

- Been in close contact with a person who had chickenpox or shingles in the past 5 years.

- VZV seronegative

- Taking systemic suppressive regular doses of drugs with anti-VZV activity such as acyclovir, famciclovir, or valacyclovir. Episodic use is allowed. For Cohort 1: medication cannot be taken 24 hours prior to or 30 days after receiving Zostavax per CDC recommendations.

- HIV seropositive.

- Hepatitis C infection or active Hepatitis B infection.

- History of a life-threatening allergic reaction (anaphylactic/anaphylactoid reaction) to gelatin, neomycin, or any other component of shingles vaccine. Neomycin allergy manifested as contact dermatitis is not an exclusion.

- Has immunosuppression as a result of an underlying illness (e.g. leukemia, lymphoma or other malignant neoplasms) or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy.

- Has long-term use of oral or parenteral steroids (>7 days), or high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (nasal and topical steroids are allowed).

- Women of child-bearing potential only: pregnant or planning to become pregnant 3 months post vaccination

- Donated blood in the past 8 weeks or planning to donate blood during the study

- Weighs less than 110 lbs

- Has any condition or medical history that would, in the opinion of the site principal investigator place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.

Additional exclusions for optional skin biopsy:

1. Has an acute or chronic medical condition that, in the opinion of the investigator, would render biopsies unsafe

2. History of coagulopathy or taking medication that may cause bleeding (long term aspirin, heparin, coumadin)

3. History of keloid formation or excessive scarring

4. History of frequent cellulitis or boils (>3 episodes in past 2 years) requiring antibiotic therapy.

5. Allergy to lidocaine, silver nitrate, or mupirocin.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Zoster Vaccine Live


Locations

Country Name City State
United States University of Washington Virology Research Clinic Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
University of Washington Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Th1 Cytokine Positive VZV-specific CD4 T-cells in Blood To determine if Zostavax, when given as FDA indicated, boosts VZV-specific T-cells in the blood 6 months
Primary Percentage of Th1 Cytokine Positive VZV-specific CD4 T-cells in Skin To determine if shingles disease boosts the local level of VZV-specific T cells in skin 4 weeks after Zostavax 4 weeks
Secondary Number of Participants With Adverse Events Due to Zostavax To measure the occurrence of adverse events after Zostavax. 6 months
See also
  Status Clinical Trial Phase
Completed NCT01132716 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions N/A
Completed NCT01132729 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions N/A
Completed NCT04099706 - Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT N/A
Completed NCT04540081 - Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer N/A
Completed NCT01527370 - Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025) Phase 3
Completed NCT00534248 - Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022) Phase 3
Completed NCT01262300 - Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents Phase 1
Completed NCT00576108 - A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN) Phase 2
Completed NCT00109122 - Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007) Phase 2
Completed NCT04047979 - Systems Biology of Zoster Vaccine Phase 2
Active, not recruiting NCT05871541 - A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine Phase 1
Completed NCT02114333 - Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds Phase 1
Completed NCT00900783 - A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster Phase 2
Completed NCT01600079 - ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
Active, not recruiting NCT02444936 - ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors Phase 4
Recruiting NCT05554068 - Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Phase 2
Recruiting NCT06238726 - Nudging Patients to Increase Shingles Vaccination N/A
Completed NCT02704572 - Optimal Timing of Zoster Vaccine After Zoster Illness N/A
Completed NCT00300222 - Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Phase 3
Terminated NCT02412917 - A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia Phase 3